Navigation Links
Self-assembling anti-cancer molecules created in minutes
Date:8/3/2014

Researchers have developed a simple and versatile method for making artificial anti-cancer molecules that mimic the properties of one of the body's natural defence systems.

The chemists, led by Professor Peter Scott at the University of Warwick, UK, have been able to produce molecules that have a similar structure to peptides which are naturally produced in the body to fight cancer and infection.

Published in Nature Chemistry, the molecules produced in the research have proved effective against colon cancer cells in laboratory tests, in collaboration with Roger Phillips at the Institute for Cancer Therapeutics, Bradford, UK.

Artificial peptides had previously been difficult and prohibitively expensive to manufacture in large quantities, but the new process takes only minutes and does not require costly equipment. Also, traditional peptides that are administered as drugs are quickly neutralised by the body's biochemical defences before they can do their job.

A form of complex chemical self-assembly, the new method developed at Warwick addresses these problems by being both practical and producing very stable molecules. The new peptide mimics, called triplexes, have a similar 3D helix form to natural peptides.

"The chemistry involved is like throwing Lego blocks into a bag, giving them a shake, and finding that you made a model of the Death Star" says Professor Scott. "The design to achieve that takes some thought and computing power, but once you've worked it out the method can be used to make a lot of complicated molecular objects."

Describing the self-assembly process behind the artificial peptides Professor Scott says: "When the organic chemicals involved, an amino alcohol derivative and a picoline, are mixed with iron chloride in a solvent, such as water or methanol, they form strong bonds and are designed to naturally fold together in minutes to form a helix. It's all thermodynamically downhill. The assembly instructions are encoded in the chemicals themselves."

"Once the solvent has been removed we are left with the peptide mimics in the form of crystals", says Professor Scott. "There are no complicated separations to do, and unlike a Lego model kit there are no mysterious bits left over. In practical terms, the chemistry is pretty conventional. The beauty is that these big molecules assemble themselves. Nature uses this kind of self-assembly to make complex asymmetric molecules like proteins all the time, but doing it artificially is a major challenge."

Whilst the peptide mimics created by the process have been successful in laboratory tests on colon cancer cells they will require further research before they can be used in clinical trials on patients. Nevertheless they are made of simple building blocks and in early tests the team have shown that they have very low toxicity to bacteria. "This is very unusual and promising selectivity," says Professor Scott.


'/>"/>

Contact: Tom Frew
A.T.Frew@warwick.ac.uk
44-247-657-5910
University of Warwick
Source:Eurekalert  

Related medicine news :

1. Self-assembling nanoparticle could improve MRI scanning for cancer diagnosis
2. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
3. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
4. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
5. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
6. Development of the first way to make large amounts of promising anti-cancer substance
7. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
8. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
9. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
10. New understanding of why anti-cancer therapy stops working at a specific stage
11. Metformin's Anti-Cancer Properties Clarified in an Obesity Cell Model of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Self-assembling anti-cancer molecules created in minutes
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
(Date:12/5/2016)... Shrewsbury, PA (PRWEB) , ... December 05, 2016 , ... ... of necessity for the betterment of both the smaller rider and the horse. Smaller ... performance. The Saddle Sidekick is designed to fit over a properly fitted western saddle ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... of physical therapist assistants, under direct supervision of a licensed physical therapist, to ... therapy receives a consultation and treatment plan from a licensed physical therapist (PT) ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic ... Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading ...
(Date:12/4/2016)... California (PRWEB) , ... December 03, 2016 , ... ... lower thirds, 4 transitions and many more tools allowing FCPX editors to create ... of Pixel Film Studios. , Perfect Harmony contains a beautifully designed 3D ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... PITTSBURGH , Dec. 5, 2016  Wellbridge Health and ... innovative digital health solutions to Medicare and Medicaid plan members ... effort targeted at the unique needs of this group of ... on social work philosophies to provide insight into members, daily ... , ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
Breaking Medicine Technology: